Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug

Eli Lilly will appeal the UK's NICE decision to not reimburse its Alzheimer's drug Kisunla, citing unreasonableness based on submitted evidence. This follows NICE deeming the drug too expensive and the EU's rejection in March due to concerns about the drug's efficacy versus the risk of brain swelling. Kisunla, like rival Leqembi, targets amyloid beta in the brain, but faces hurdles including cost concerns and slow adoption in the US due to complexities in administration and monitoring.

Analysis

Eli Lilly (LLY.N) has announced its intention to appeal the UK's National Institute for Health and Care Excellence (NICE) recommendation against reimbursing its Alzheimer's drug, Kisunla, for use within the state-run health service. NICE had previously deemed Kisunla, approved in the UK in the prior year for mild cognitive impairment and mild dementia due to Alzheimer's, too expensive for widespread public funding based on its cost-effectiveness assessment. This decision represents another significant setback for Kisunla, following a March rejection by the EU medicines regulator, which cited concerns that the treatment's ability to slow cognitive decline was not significant enough to outweigh the risk of serious brain swelling in patients. A rival drug, Leqembi from Eisai (4523.T) and Biogen (BIIB.O), which similarly targets amyloid beta protein in the brain, was also deemed too costly by NICE for the UK's health service in August of the previous year. The broader market adoption of these amyloid-targeting Alzheimer's treatments has been notably slow, even in the United States, attributed to complexities surrounding their administration, including the requirement for additional diagnostic tests and regular brain scans to monitor for potentially serious side effects. The moderately negative sentiment associated with this development (-0.5 overall, with a more specific -0.7 for LLY) underscores the accumulating hurdles to market access and commercial viability for this new class of Alzheimer's therapies.

Key Decisions for Investors

• Investors in Eli Lilly should closely monitor the outcome of the appeal against NICE's decision, as a sustained negative reimbursement recommendation in the UK, combined with the prior EU rejection, could materially constrain Kisunla's revenue potential in key European markets.
• The recurring cost-effectiveness challenges highlighted by NICE for both Kisunla and Leqembi indicate a significant systemic barrier for this class of Alzheimer's drugs in markets with public healthcare systems, potentially impacting long-term global sales forecasts if similar pricing pressures emerge elsewhere.
• It is prudent to factor in the heightened regulatory, reimbursement, and practical adoption risks associated with Alzheimer's drug development, as complexities in administration and side-effect monitoring are currently impeding market penetration even where regulatory approvals have been granted.